Dr. Tillman Gerngross joined SV in 2006. He is involved in the review of investment opportunities in the therapeutic protein and antibody space as well as evaluating new startup opportunities.
Tillman is the co-founder and CEO of Adimab, a SV Fund IV portfolio company. He is also the co-founder of Arsanis, a company focused on the development of antibodies against infectious diseases (SV Fund V). Tillman holds faculty positions at the Engineering School at Dartmouth College, as well as the Departments of Biology and Chemistry.
Previously, Tillman was a co-founder of GlycoFi, Inc. (SV Fund III) and served as the company’s Chief Scientific Officer until its acquisition by Merck and Co in June of 2006. From 1989-93 he was a visiting scientist and later Postdoctoral Fellow at MIT.
MS, Chemical Engineering; PhD, Molecular Biology, Technical University of Vienna; Postdoctorate, MIT